| Identification | Back Directory | [Name]
Pyrrolo[1,2-c]pyrimidine-2(1H)-acetamide, 6-[5-chloro-2-[(tetrahydro-2H-pyran-4-yl)amino]-4-pyrimidinyl]-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]-3,4-dihydro-α-methyl-1-oxo-, (αR)- | [CAS]
2560552-75-0 | [Synonyms]
ERK1/2 inhibitor 5
Pyrrolo[1,2-c]pyrimidine-2(1H)-acetamide, 6-[5-chloro-2-[(tetrahydro-2H-pyran-4-yl)amino]-4-pyrimidinyl]-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]-3,4-dihydro-α-methyl-1-oxo-, (αR)- | [Molecular Formula]
C28H32ClFN6O5 | [MOL File]
2560552-75-0.mol | [Molecular Weight]
587.05 |
| Hazard Information | Back Directory | [Uses]
ERK1/2 inhibitor 5 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 5 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2020238776A1)[1]. | [References]
[1] Xin Li, et al. Substituted condensed bicyclic derivatives, their preparation method and their application in medicine. Patent WO2020238776A1. |
|
|